Pegvisomant
Pegvisomant
Pegvisomant (pronounced: peg-vi-so-mant) is a growth hormone receptor antagonist used in the treatment of acromegaly. It is a genetically engineered analogue of human growth hormone that differs from the natural hormone by the substitution of 191 amino acid residues and the addition of a polyethylene glycol (PEG) molecule.
Etymology
The name "Pegvisomant" is derived from the words "PEG", an abbreviation for polyethylene glycol, and "visomant", which is a combination of Latin roots "viso" (meaning "to look at") and "mantis" (meaning "prophet"). This name reflects the drug's function as a growth hormone receptor antagonist.
Usage
Pegvisomant is used to treat acromegaly, a condition characterized by the overproduction of growth hormone and subsequent enlargement of body tissues. It works by blocking the action of growth hormone, thereby reducing symptoms of the condition.
Related Terms
Side Effects
Like all medications, Pegvisomant can cause side effects. Common side effects include liver damage, injection site reactions, and flu-like symptoms. Less common but more serious side effects can include tumor growth.
Precautions
Before starting treatment with Pegvisomant, patients should inform their healthcare provider about any existing health conditions, especially liver disease. Regular monitoring of liver function is recommended during treatment.
Interactions
Pegvisomant may interact with other medications, including insulin and oral hypoglycemic agents. Patients should inform their healthcare provider about all medications they are currently taking.
External links
- Medical encyclopedia article on Pegvisomant
- Wikipedia's article - Pegvisomant
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski